Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Metastatic triple-negative breast cancer, drawn from the whole corpus: 164 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Cross-resistance between antibody-drug conjugates sharing a topoisomerase I payload.
Nothing recorded yet.
Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
No biomarker selects patients for TROP2 drugs.
Brain metastases remain undertreated and are excluded from most trials.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Access: the new first-line drugs cost many times more than chemotherapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 27 changes by month →When this page itself was last checked or edited.
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Overall survival 17.
A milestone in how this cancer is treated.
PFS HR 0.
PFS HR 0.